A type III complement factor D deficiency: Structural insights for inhibition of the alternative pathway - 04/07/18
Doi : 10.1016/j.jaci.2018.01.048
Christopher C.T. Sng, MB BChir a, ∗, Sorcha O'Byrne, BSc b, ∗, Daniil M. Prigozhin, PhD c, ∗, Matthias R. Bauer, PhD d, ∗, Jennifer C. Harvey, BSc e, Michelle Ruhle, BBiomedSc f, Ben G. Challis, PhD g, Sara Lear, MBBS b, Lee D. Roberts, PhD h, Sarita Workman, RN MSc e, Tobias Janowitz, PhD a, Lukasz Magiera, PhD a, Rainer Doffinger, PhD FRCPath b, Matthew S. Buckland, PhD FRCPath e, Duncan J. Jodrell, DM MSc FRCP a, Robert K. Semple, MB PhD g, i, Timothy J. Wilson, PhD j, Yorgo Modis, PhD c, James E.D. Thaventhiran, PhD FRCPath a, b, k, l 
a Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
b Department of Clinical Immunology, Cambridge University Hospitals National Health Service Trust, Addenbrooke's Hospital, Cambridge, United Kingdom
c Molecular Immunity Unit, Department of Medicine, Medical Research Council (MRC) Laboratory of Molecular Biology, Cambridge, United Kingdom
d Division of Structural Studies, MRC Laboratory of Molecular Biology, Cambridge, United Kingdom
e Department of Immunology, Royal Free London National Health Service Foundation Trust, London, United Kingdom
f Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
g Wellcome Trust–MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, United Kingdom
k Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom
h Leeds Institute of Cardiovascular and Metabolic Medicine, Leeds Institute of Genetics, Health and Therapeutics (LIGHT) Laboratories, University of Leeds, Leeds, United Kingdom
i University of Edinburgh Centre for Cardiovascular Sciences, Queen's Medical Research Institute, Little France Crescent, Edinburgh, United Kingdom
j Department of Microbiology, Miami University, Oxford, Ohio
l MRC Toxicology Unit, University of Leicester, Leicester, United Kingdom
| J.E.D.T. is supported by an MRC Clinician Scientist Fellowship (MR/L006197/1). This work was funded by Cambridge Biomedical Research Centre Inflammation, Infection and Immunotherapeutics Pump-Priming Grant (BRC III PPG) funding and a Wellcome Trust Senior Research Fellowship to Y.M. (101908/Z/13/Z). R.K.S. is funded by the Wellcome Trust (grant WT098498 and strategic award 100574/Z/12/Z), the United Kingdom Medical Research Council (MRC_MC_UU_12012/5), and the United Kingdom National Institute for Health Research, Cambridge Biomedical Research Centre. T.J. is funded by Cancer Research UK (Clinician Scientist Fellowship C42738/A24868). B.G.C. is now a full-time employee of AstraZeneca. |
|
| Disclosure of potential conflict of interest: B. Challis is employee of AstraZeneca. S. Lear's institution received a grant from Cambridge Biomedical Research Centre Pump Priming Grant for this work. S. Workman received a grant from CSL Behring for other works; honorariums from LFB S.A. (France) and Biotest; and support for meetings from Grifols, CSL Behring, Bio Products Laboratory Ltd, and Octapharma. The rest of the authors declare they have no relevant conflict of interest. |
© 2018
The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 142 - N° 1
P. 311 - juillet 2018 Retour au numéro
Article précédent
- Glutathione and arginine levels: Predictors for acetaminophen-associated asthma exacerbation?
- Claudia R. Morris, David T. Mauger, Jung H. Suh, Wanda Phipatanakul, William J. Sheehan, James N. Moy, Ian M. Paul, Stanley J. Szefler, Daniel J. Jackson, Anne M. Fitzpatrick
- Nasal epithelium as a proxy for bronchial epithelium for smoking-induced gene expression and expression Quantitative Trait Loci
- Kai Imkamp, Marijn Berg, Cornelis J. Vermeulen, Irene H. Heijink, Victor Guryev, Huib A.M. Kerstjens, Gerard H. Koppelman, Maarten van den Berge, Alen Faiz
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?